Extended-Duration Thromboprophylaxis with Oral Rivaroxaban Versus Subcutaneous Enoxaparin After Total Hip Arthroplasty: RECORD1

Thromboprophylaxis is recommended for at least 10 days and up to 35 days following total hip arthroplasty (THA). Rivaroxaban is an oral, direct Factor Xa inhibitor that showed promise in early clinical trials. The purpose of this randomized, double-blind, double-dummy, phase III study was to compare the efficacy and safety of oral rivaroxaban with subcutaneous enoxaparin for 5 weeks, to prevent venous thromboembolism (VTE) in patients undergoing primary THA.